
    
      All eligible patients will receive induction chemotherapy prior to consideration of primary
      surgical intervention. If surgical intervention is deemed not to be in the best interest of
      the patient, patient will go off study at the time of evaluation for surgery. Upon completion
      of chemotherapy and surgery, all ER + and/or PR + patients will be placed on Tamoxifen 20
      mg/qd or an aromatase inhibitor.

      Induction preoperative therapy:

        -  Bevacizumab

        -  Trastuzumab

        -  ABI-007

        -  Carboplatin

      Postoperative Adjuvant Therapy:

        -  Bevacizumab

        -  Trastuzumab
    
  